rosiglitazone has been researched along with erlotinib hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brdar, I; Deng, X; Faessler, R; Mani, NS; Roessler, A; Sales, ZS; Wu, J | 1 |
| Endo, S; Furukawa, C; Hasegawa, H; Ikari, A; Manabe, A; Matsunaga, T | 1 |
2 other study(ies) available for rosiglitazone and erlotinib hydrochloride
| Article | Year |
|---|---|
Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3.
Topics: Amides; Amination; Aniline Compounds; Anticholesteremic Agents; Azabicyclo Compounds; Benzamides; Catalysis; Chemistry, Pharmaceutical; Erlotinib Hydrochloride; Eszopiclone; Fluorobenzenes; Heterocyclic Compounds; Humans; Hydrogen-Ion Concentration; Hypnotics and Sedatives; Hypoglycemic Agents; Imatinib Mesylate; Molecular Structure; Phosphorus Compounds; Piperazines; Prescription Drugs; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones; Urea | 2011 |
Upregulation of transient receptor potential melastatin 6 channel expression by rosiglitazone and all-trans-retinoic acid in erlotinib-treated renal tubular epithelial cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Epithelial Cells; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kidney Tubules; MAP Kinase Signaling System; PPAR gamma; Protein Transport; Rats; Receptors, Retinoic Acid; Rosiglitazone; Tretinoin; TRPM Cation Channels; Up-Regulation | 2019 |